Itolizumab

Equillium, Inc.（纳斯达克代码：EQ）在 12 月份的空头头寸增加了 22.7%，截至 12 月 15 日，总计 944,698 股。这占公司已售空股票的 2.2%，根据平均每日成交量 512,122 股，空头头寸比率为 1.8 天。股票价格保持在 1.55 美元，52 周范围为 0.27 美元至 2.35 美元。最近的内部交易包括首席运营官 Christine Zedelmayer 出售了 100,000 股。机构投资者持有该股票的 27.05%，分析师对公司的评级褒贬不一Equillium, Inc.（纳斯达克代码：EQ - 获取免费报告）在 12 月份的空头头寸大幅增加。截至 12 月 15 日，空头头寸总计为 944,698 股，比 11 月 30 日的 770,137 股增加了 22.7%。根据平均每日交易量 512,122 股，目前的空头头寸比率为 1.8 天。目前，该公司的 2.2% 股份被做空。 Equillium 价格表现 2026 年将主导的三大投资主题 在周三的交易时段，Equillium 股票价格保持在 1.55 美元。该股票的交易量为 535,719 股，而其平均交易量为 964,886 股。该股票的 50 日移动平均价格为 1.16 美元，200 日移动平均价格为 1.07 美元。Equillium 的 52 周低点为 0.27 美元，52 周高点为 2.35 美元。 Equillium（纳斯达克代码：EQ - 获取免费报告）最近于 11 月 13 日发布了其财报。公司报告每股收益（EPS）为（0.06 美元），超出市场共识预期的（0.14 美元）0.08 美元。分析师平均预计 Equillium 在本年度的每股收益为 0.14 美元。 内部人士下注 利用 2026 年人工智能基础设施的增长，投资这只高增长 ETF 在其他新闻中，首席运营官 Christine Zedelmayer 于 12 月 23 日（星期二）出售了 100,000 股该股票，交易价格为 1.50 美元，总交易额为 150,000.00 美元。交易后，首席运营官直接持有公司 91,444 股股票，价值 137,166 美元。这代表其持股减少了 52.23%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接查看。在过去的 90 天内，内部人士已出售 143,802 股公司股票，价值 205,179 美元。目前，31.60% 的股票由内部人士持有。 对 Equillium 的对冲基金看法 一些对冲基金和其他机构投资者最近调整了对该股票的持有。ADAR1 Capital Management LLC 在第三季度购买了 Equillium 的新股份，价值 7,951,000 美元。Woodline Partners LP 在第三季度购买了 Equillium 的股份，价值约 5,018,000 美元。Vanguard Group Inc.在第三季度将其在 Equillium 的持股增加了 59.4%。Vanguard Group Inc.目前持有 1,313,946 股公司股票，价值 1,879,000 美元，此前在上个季度又购买了 489,855 股。Two Sigma Investments LP 在第三季度购买了 Equillium 的新股份，价值约 190,000 美元。最后，Schonfeld Strategic Advisors LLC 在第三季度购买了 Equillium 的新股份，价值约 178,000 美元。机构投资者目前持有公司 27.05% 的股票。 分析师评级变动 5 只推动下一个增长浪潮的人工智能基础设施股票 几家研究公司最近对 EQ 发表了评论。Weiss Ratings 在周一的研究报告中重申了对 Equillium 的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 15 日（星期六）的研究报告中将 Equillium 的评级从 “卖出” 上调至 “持有”。两位研究分析师对该股票给予了 “持有” 评级，一位则对公司的股票给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “减持”，平均目标价格为 1.00 美元。 查看我们对 EQ 的最新分析 Equillium 公司简介 （获取免费报告） Equillium, Inc.（纳斯达克代码：EQ）是一家临床阶段的生物制药公司，专注于开发新型免疫疗法以治疗严重的自身免疫疾病和防止器官移植排斥反应。公司的主要治疗候选药物 EQ001（itolizumab）是一种人源化单克隆抗体，通过靶向 CD6 受体来调节 T 细胞的激活。Equillium 的产品线还包括其他生物候选药物，旨在解决急性移植物抗宿主病（GVHD）和狼疮性肾炎等适应症。 Equillium 成立于 2015 年，总部位于加利福尼亚州拉荷亚，从 Biocon Limited 获得了 itolizumab 的许可，利用该抗体在早期临床研究中的既定安全性。 另见 我们更看好的五只股票比 Equillium 更好 请勿删除，立即阅读 崩盘已经开始（大多数人只是不知道而已） 警报：在 2026 年 1 月之前抛售这 5 只股票！ [无脑黄金投资]：“给我一个更好的投资。” 投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发 此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。 你现在应该投资 1,000 美元在 Equillium 吗？ 在考虑 Equillium 之前，你需要听听这个。 MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Equillium 并不在名单上。 虽然 Equillium 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。 在这里查看这五只股票 Equillium, Inc.（纳斯达克代码：EQ - 获取免费报告）在 12 月份的空头头寸大幅增加。截至 12 月 15 日，空头头寸总计为 944,698 股，比 11 月 30 日的 770,137 股增加了 22.7%。根据平均每日交易量 512,122 股，目前的空头头寸比率为 1.8 天。目前，该公司的 2.2% 股份被做空。 Equillium 价格表现 2026 年将主导的三大投资主题 在周三的交易时段，Equillium 股票价格保持在 1.55 美元。该股票的交易量为 535,719 股，而其平均交易量为 964,886 股。该股票的 50 日移动平均价格为 1.16 美元，200 日移动平均价格为 1.07 美元。Equillium 的 52 周低点为 0.27 美元，52 周高点为 2.35 美元。 Equillium（纳斯达克代码：EQ - 获取免费报告）最近于 11 月 13 日发布了其财报。公司报告每股收益（EPS）为（0.06 美元），超出市场共识预期的（0.14 美元）0.08 美元。分析师平均预计 Equillium 在本年度的每股收益为 0.14 美元。 内部人士下注 利用 2026 年人工智能基础设施的增长，投资这只高增长 ETF 在其他新闻中，首席运营官 Christine Zedelmayer 于 12 月 23 日（星期二）出售了 100,000 股该股票，交易价格为 1.50 美元，总交易额为 150,000.00 美元。交易后，首席运营官直接持有公司 91,444 股股票，价值 137,166 美元。这代表其持股减少了 52.23%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接查看。在过去的 90 天内，内部人士已出售 143,802 股公司股票，价值 205,179 美元。目前，31.60% 的股票由内部人士持有。 对 Equillium 的对冲基金看法 一些对冲基金和其他机构投资者最近调整了对该股票的持有。ADAR1 Capital Management LLC 在第三季度购买了 Equillium 的新股份，价值 7,951,000 美元。Woodline Partners LP 在第三季度购买了 Equillium 的股份，价值约 5,018,000 美元。Vanguard Group Inc.在第三季度将其在 Equillium 的持股增加了 59.4%。Vanguard Group Inc.目前持有 1,313,946 股公司股票，价值 1,879,000 美元，此前在上个季度又购买了 489,855 股。Two Sigma Investments LP 在第三季度购买了 Equillium 的新股份，价值约 190,000 美元。最后，Schonfeld Strategic Advisors LLC 在第三季度购买了 Equillium 的新股份，价值约 178,000 美元。机构投资者目前持有公司 27.05% 的股票。 分析师评级变动 5 只推动下一个增长浪潮的人工智能基础设施股票 几家研究公司最近对 EQ 发表了评论。Weiss Ratings 在周一的研究报告中重申了对 Equillium 的 “卖出（d-）” 评级。华尔街 Zen 在 11 月 15 日（星期六）的研究报告中将 Equillium 的评级从 “卖出” 上调至 “持有”。两位研究分析师对该股票给予了 “持有” 评级，一位则对公司的股票给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的平均评级为 “减持”，平均目标价格为 1.00 美元。 查看我们对 EQ 的最新分析 Equillium 公司简介 （获取免费报告） Equillium, Inc.（纳斯达克代码：EQ）是一家临床阶段的生物制药公司，专注于开发新型免疫疗法以治疗严重的自身免疫疾病和防止器官移植排斥反应。公司的主要治疗候选药物 EQ001（itolizumab）是一种人源化单克隆抗体，通过靶向 CD6 受体来调节 T 细胞的激活。Equillium 的产品线还包括其他生物候选药物，旨在解决急性移植物抗宿主病（GVHD）和狼疮性肾炎等适应症。 Equillium 成立于 2015 年，总部位于加利福尼亚州拉荷亚，从 Biocon Limited 获得了 itolizumab 的许可，利用该抗体在早期临床研究中的既定安全性。 另见 我们更看好的五只股票比 Equillium 更好 请勿删除，立即阅读 崩盘已经开始（大多数人只是不知道而已） 警报：在 2026 年 1 月之前抛售这 5 只股票！ [无脑黄金投资]：“给我一个更好的投资。” 投资者警报：微小的 “3 美元人工智能奇迹股票” 即将爆发 此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。 你现在应该投资 1,000 美元在 Equillium 吗？ 在考虑 Equillium 之前，你需要听听这个。 MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Equillium 并不在名单上。 虽然 Equillium 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。 在这里查看这五只股票

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. “Our recent financing has enabled us to accelerate the development of our novel AhR modulator, EQ504, which we believe has potential to be a first-in-class, oral and colon-targeted therapeutic for ulcerative colitis (UC),” said Bruce Steel, chief executive officer at Equillium. “We are advancing rapidly through our preclinical work and expect to be ready to initiate the Phase 1 clinical study in mid-2026 with the potential to achieve proof-of-concept with the addition of UC patient cohorts following the SAD/MAD portion of the study.” Recent Corporate & Clinical Highlights: On August 11th 2025, the Company announced it entered into a private placement with leading healthcare investors providing up to $50 million in gross proceeds. The private placement was comprised of an initial upfront financing of approximately $30 million in gross proceeds, with the potential for up to an additional $20 million in gross proceeds at the initiation of clinical studies with EQ504 and the occurrence of the other milestones set forth in the purchase agreement for the private placement. The initial tranche of the financing is expected to fund Company operations through 2027. The financing was led by new investors ADAR1 Capital Management and Janus Henderson Investors, and included participation from additional new investors Adage Capital Partners LP, Coastlands Capital, and Woodline Partners LP. On November 5th 2025, the Company hosted a virtual KOL investor event featuring Dr. Francisco Quintana (Harvard Medical School, Broad Institute) and Dr. Brian Feagan (Western University, Alimentiv). The session focused on the growing importance of AhR modulation as a next-generation therapeutic strategy for immune-mediated diseases and reviewed the potential of EQ504 in UC. Key highlights include: AhR modulation is i) a differentiated and multi-modal approach to decreasing tissue inflammation while promoting tissue repair; and ii) clinically validated in skin and GI diseases, through VTAMA® and the botanical indigo naturalis, respectively. EQ504 i) is a potent and selective AhR modulator that may be administered orally and is formulated to target the colon, representing a next-generation therapeutic to treat UC locally; and ii) has broad therapeutic potential in UC as a potential standalone oral therapy, or in combination with other therapeutic approaches. A replay of the KOL event is available here. Anticipated Upcoming Milestones: EQ504 Phase 1 study is expected to initiate in mid-2026. Third Quarter 2025 Financial Results Revenue for the third quarter of 2025 was $0, compared with $12.2 million for the same period in 2024. Revenue in 2024 consisted entirely of itolizumab development funding and amortization of the upfront payment from Ono Pharmaceutical related to the Asset Purchase Agreement that was terminated in October 2024. Research and development (R&D) expenses for the third quarter of 2025 were $1.3 million, compared with $9.6 million for the same period in 2024. The significant decrease in R&D expenses was primarily driven by lower clinical development expenses, lower CMC activities, and lower consulting expenses primarily related to the wind down of our EQUATOR study as well as lower employee compensation and benefits due to lower headcount caused by the wind down of our clinical studies. General and administrative (G&A) expenses for the third quarter of 2025 were $3.3 million, unchanged from $3.3 million for the same period in 2024. Net loss for the third quarter of 2025 was $4.2 million, or $(0.06) per basic and diluted share, compared with a net loss of $7,000, or $(0.00) per basic and diluted share for the same period in 2024. The increase in net loss for the period was primarily due to lower revenue partially offset by lower operating expenses. Cash, cash equivalents and short-term investments totaled $33.1 million as of September 30, 2025, compared to $22.6 million as of December 31, 2024. Equillium believes that its cash and cash equivalents on the balance sheet as of September 30, 2025 are capable of funding its currently planned operations through 2027, based on certain assumptions and estimates that may prove to be inaccurate. About EQ504 EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases. About Equillium Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways. For more information, visit www.equilliumbio.com. Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding the potential for Equillium to receive the additional $20 million in gross proceeds from the private placement upon the completion of the milestones set forth in the purchase agreement for the private placement; Equillium’s expectation that the net proceeds from the private placement will fund its operations through 2027; Equillium’s expected use of the net proceeds from the private placement; Equillium’s intent to prioritize development of EQ504 and the ability to accelerate such development; the potential benefits of Equillium’s product candidates; and other statements that are not historical facts. These statements are based on Equillium’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include, but are not limited to: market conditions; volatility in the trading price of Equillium’s common stock; the sufficiency of Equillium’s capital resources and need for additional capital to achieve its goals; Equillium’s ability to raise additional capital on terms acceptable to Equillium, or at all; Equillium’s ability to continue as a going concern; risks inherent in achieving clinical milestones and stock price thresholds; Equillium’s ability to initiate or progress a Phase 1 clinical study, or any clinical trials, on the anticipated timelines, if at all; Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies, if and when initiated; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and changes in Equillium’s strategic plans. The foregoing list of risk factors is not exhaustive. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports with the Securities and Exchange Commission (SEC), which may be accessed for free by visiting the SEC’s website at www.sec.gov, and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Contact PJ Kelleher LifeSci Advisors, LLC +1-617-430-7579 pkelleher@lifesciadvisors.com